Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

KalVista Pharmaceuticals (KALV) Assets Average (2017 - 2024)

KalVista Pharmaceuticals' Assets Average history spans 9 years, with the latest figure at $227.8 million for Q4 2024.

  • For Q4 2024, Assets Average changed N/A year-over-year to $227.8 million; the TTM value through Dec 2024 reached $227.8 million, changed N/A, while the annual FY2020 figure was $105.3 million, 17.35% up from the prior year.
  • Assets Average for Q4 2024 was $227.8 million at KalVista Pharmaceuticals, up from $180.5 million in the prior quarter.
  • Across five years, Assets Average topped out at $227.8 million in Q4 2024 and bottomed at $70.8 million in Q1 2021.
  • The 4-year median for Assets Average is $119.8 million (2023), against an average of $136.2 million.
  • The largest annual shift saw Assets Average plummeted 34.11% in 2021 before it surged 92.29% in 2024.
  • A 4-year view of Assets Average shows it stood at $79.7 million in 2020, then fell by 11.11% to $70.8 million in 2021, then skyrocketed by 111.13% to $149.5 million in 2023, then soared by 52.35% to $227.8 million in 2024.
  • Per Business Quant, the three most recent readings for KALV's Assets Average are $227.8 million (Q4 2024), $180.5 million (Q4 2024), and $217.8 million (Q3 2024).